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AbsTRACT
background and objectives With high rates of use 
and uncertain consequences, valid electronic cigarette 
(e-cigarette) use frequency and addiction measures 
for adolescents are needed. This cross-sectional 
study examined correlations for multiple measures 
of adolescent e-cigarette use with nicotine exposure 
quantified with salivary cotinine levels.
Methods Adolescents (N=173, age 13–18) who 
reported past-month e-cigarette use were recruited from 
the San Francisco Bay Area. Participants self-reported: 
(1) days of e-cigarette use in a typical month, (2) number 
of e-cigarette sessions in a typical day (sessions per day; 
SPD) and the (3) E-Cigarette Addiction Severity Index 
(EASI). Participants also completed the 10-item Penn 
State Electronic Cigarette Dependence Index (ECDI), 
which we examined in full and as a 2-item Heaviness 
of Vaping Index (HVI; the sum of the ECDI items on 
use frequency and time to first vaping on wakening). 
Sessions per month (SPM) were calculated using days 
per month and SPD. Cotinine levels, SPD and SPM were 
log-transformed.
Results Among frequency measures, SPM correlated 
most strongly with cotinine (r=0.59), followed closely by 
days per month (r=0.58) and SPD (r=0.57), p<0.001. 
Among dependence measures, the EASI correlated most 
strongly with cotinine (r=0.51), closely followed by the 
ECDI and HVI (r’s=0.50), all p’s<0.001.
Conclusions Adolescents’ reports of frequency of 
e-cigarette use and degree of addiction correlated 
significantly with cotinine as a biomarker of nicotine 
exposure. We recommend the EASI and days per month 
as brief general measures. SPM and the ECDI are more 
extensive measures that may yield a more nuanced 
understanding of use.
InTRoduCTIon
Electronic cigarette (e-cigarette) use among adoles-
cents is a public health concern. E-cigarette use (also 
known as vaping) exposes adolescents to nicotine and 
toxicants,1–9 and may increase the risk for initiating 
combustible cigarette use.10 11 Most epidemiological 
investigations of adolescent e-cigarette use to date 
have assessed lifetime or past month use, rather than 
heaviness of use. To better approximate estimates 
of safety and harm, in research and in clinical prac-
tice, valid measures of adolescents’ e-cigarette use 
frequency and dependence are needed. Furthermore, 
few studies have biochemically validated adolescents’ 
self-reported e-cigarette use. Consensus in measure-
ment is needed to compare results across studies. The 
relative strength of associations between biochemical 
markers of e-cigarette use and self-reported measures 
of adolescent e-cigarette frequency and the develop-
ment of e-cigarette addiction has not yet been exam-
ined. The current study sought to fill these gaps.
Some studies have measured frequency of e-cig-
arette use in reported daily number of cartridges12 
which would not be applicable to those who do not 
use cartridges or who share e-cigarettes with friends. 
In the extant literature to date, days of e-cigarette 
use per month has been the most popular measure of 
adolescent e-cigarette use frequency.13–15 Although 
days per month may capture differences between 
daily use and social (eg, weekend only) use, it does 
not differentiate between using once versus multiple 
times per day. Instead, the number of use sessions 
per day (SPD) may be important to measure and 
may serve as an analogue for cigarettes per day, an 
established measure of smoking heaviness.16 Alter-
natively, a combination measure of sessions per 
month (SPM) may be the most accurate measure of 
adolescents’ e-cigarette use frequency, as it accounts 
for both days per month and SPD.
As with combustible cigarette smoking, nicotine 
exposure is critical to the development of addiction 
to e-cigarettes.17 Consequently, a strong correla-
tion should exist between nicotine exposure and 
perceived e-cigarette addiction among adolescent 
e-cigarette users. The Penn State E-Cigarette Depen-
dence Index18 (ECDI) has been validated in adults 
and has been used limitedly to measure dependence 
in adolescents.15 To the best of our knowledge, the 
ECDI has not been examined in association with 
actual nicotine exposure in adolescents. Heavi-
ness of vaping (HVI), an index combining time 
to first e-cigarette use on awakening and number 
of daily sessions, is another potentially useful 
measure of e-cigarette dependence.19 HVI is based 
on the Heaviness of Smoking Index,16 which was 
derived from the classic Fagerström Test of Ciga-
rette Dependence. Since e-cigarettes are more easily 
concealed than combustible cigarettes, they can be 
used surreptitiously in an adolescent’s home first 
thing in the morning. Therefore, time to first e-cig-
arette and frequency of use may be more applicable 
as a combined measure of adolescents’ e-cigarette 
dependence than they were for adolescents’ tradi-
tional cigarette dependence. Finally, self-described 
level of e-cigarette addiction, as a single item, may 
be an efficient and helpful measure of adolescents’ 
dependence on e-cigarettes. The item, which we call 
the E-Cigarette Addiction Severity Index (EASI), is 
based on a parallel item for combustible cigarettes, 
which in adolescent smokers we found to correlate 
significantly with cotinine.20
To determine the most accurate self-report 
methods for estimating nicotine intake among 
adolescent e-cigarette users, the present study 
assessed the concordance between multiple self-re-
port measures of e-cigarette frequency and depen-
dence and salivary cotinine, a biomarker of nicotine 
exposure. Because adolescent dual users of e-cig-
arettes and combustible cigarettes are exposed to 
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nicotine from both sources, a secondary analysis included only 
those participants without significant recent nicotine exposure 
from combustible cigarettes.
PATIenTs And MeThods
Participants and procedures
Adolescent e-cigarette users (ages 13–18, N=173) who reported 
past month e-cigarette use were recruited from the San Francisco 
Bay Area using advertisements posted on social media and in the 
community and by word-of-mouth. Eligibility criteria (assessed 
during phone screening) were past-month e-cigarette use and at 
least 10 lifetime use sessions. Eligible participants were sched-
uled for an initial, in-person session during which they provided 
informed consent, completed self-report measures and provided 
saliva and urine samples for biomarker testing. Sessions took 
place between 5/27/15 and 4/7/17. Compensation was $30.
Measures
Descriptive characteristics
Participants provided basic demographic information, charac-
teristics of their e-cigarette use (eg, age of first use, preferred 
device, nicotine content)15 and past 30 days’ and past 24 hours’ 
tobacco smoking.
E-cigarette use frequency measures
Participants self-reported e-cigarette use days in a typical month 
and e-cigarette use sessions on each day of a typical week. Specif-
ically, they answered: ‘In a typical month (ie, 30 days), on how 
many days do you use e-cigarettes?’ (0–30) and, ‘In a typical 
week, please write the number of sessions you typically use your 
e-cigarette on each day’ (seven items, measuring sessions from 
Monday to Sunday). ‘Sessions’ were defined for participants as, 
‘a period or block of time when you are vaping’.
E-cigarette dependence/addiction
We evaluated three measures of e-cigarette dependence/addic-
tion. The first was the 10-item Penn State Electronic Cigarette 
Dependence Index (ECDI).18 In addition to SPD, the ECDI 
included items such as, ‘Do you use an e-cigarette now because 
it is really hard to quit?’ (yes/no) and ‘Do you ever have strong 
cravings to use an electronic cigarette?’ (yes/no). From the ECDI 
items, we also calculated a Heaviness of Vaping Index (HVI) 
summing the items measuring frequency of use in a day and 
time to first e-cigarette assessed as: ‘On days that you can use 
your electronic cigarette freely, how soon after you wake up do 
you first use your electronic cigarette?’ (coded as 0–5 min=5, 
6–15 min=4, 16–30 min=3, 31–60 min=2, 61–120 min=1, 
121+min=0).21 22 Lastly, we tested a novel single item, the 
EASI, self-reported as: ‘On a scale of 0%–100% (not addicted to 
extremely addicted), how addicted to e-cigarettes do you think 
you are?’ Full scoring information for frequency and dependence 
measures is presented in online supplementary table 1.
Biomarkers of nicotine and tobacco exposure
Salivary cotinine was measured as a biochemical marker of nico-
tine exposure. Cotinine has a half-life of approximately 16–19 
hours and remains detectable for up to 3 days after nicotine expo-
sure.23 Urinary nitrosamine 4-(methylnitrosamino)−1-(3-pyr-
idyl)−1-butanol (NNAL), a tobacco-specific metabolite, was 
measured to detect recent combustible tobacco use. NNAL has 
a half-life of 10–18 days and remains detectable for 6–12 weeks 
after combustible tobacco exposure.24 NNAL concentrations 
were normalised for creatinine25 and should not be present in 
levels above 10 pg/mg creatinine in adolescents with no recent 
active smoking and either past smoking or light secondhand 
smoke exposure (neither of which would be expected to signifi-
cantly affect cotinine).26 Saliva and urine samples were analysed 
at the Clinical Pharmacology Laboratory at the University of 
California, San Francisco. Analyses were performed using liquid 
chromatography-tandem mass spectrometry.27
statistical analysis
An averaged SPD variable was computed from dividing the item 
assessing ‘sessions per day of the week’ by seven. A calculated 
SPM variable was created by multiplying SPD by ‘days of use 
per month’. Due to non-normal distributions, SPD, SPM and 
cotinine level were log-transformed. Correlations were exam-
ined for cotinine with days per month, SPD, SPM, self-de-
scribed degree of e-cigarette addiction, the 10-item ECDI total 
score and the 2-item HVI. There were no missing data on the 
variables of interest. Analyses were conducted in both the full 
sample (N=173) and in the subsample of e-cigarette only users 
(N=144). As described above, e-cigarette only users were defined 
as adolescents who reported no combustible cigarette use in the 
past 24 hours and had NNAL levels<10 pg/mL creatinine.26 Due 
to rapid changes in e-cigarette product availability and regula-
tion, partial correlations were also examined, adjusting for date 
of assessment (ie, days passed from assessment date to present 
date).
ResulTs
Three hundred and eighty-six adolescents were screened, 
229 were found to be eligible and 180 agreed to participate. 
Of the 180 who completed a baseline survey, 173 adolescents 
met criteria for using an e-cigarette at least once in the prior 
30 days and at least 10 lifetime uses. The sample was 75.1% 
male and 54.9% non-Hispanic white with a mean age of 16.6 
years (SD=1.2, range 13–18). The mean age of initiating e-ciga-
rette use was age 14.8 (SD=1.3, range 10–17); 26.6% reported 
smoking a cigarette in the past 30 days and 5.0% smoked a ciga-
rette in the past 24 hours. On average, participants reported 
using e-cigarettes approximately every other day (days per 
month M=15.4, SD=9.8). Median SPD were 1.4 (IQR: 2.7), 
and median SPM were 17.3 (IQR: 74.4). Participants’ e-cigarette 
use characteristics and cotinine levels are presented in table 1.
Distributions of the sample’s responses on the measures are 
reported in table 2. Among frequency measures, SPM (r=0.59) 
was most strongly correlated with cotinine levels, followed by 
days per month (r=0.58) and SPD (r=0.57). All three depen-
dence measures correlated significantly with cotinine: the 
single item EASI (r=0.51), the 2-item HVI (r=0.50) and the 
10-item ECDI (r=0.50). Mean scores on the EASI (M=24.6%, 
SD=25%), ECDI (M=3.4, SD=3.9) and HVI (M=1.8, SD=2.3) 
reflected fairly low dependence in the sample. The proportion 
scoring as moderately to heavily addicted or dependent were: 
15.6% with an EASI score >50%, 13.3% with an ECDI score 
>8 and 4.6% with an HVI score >6 out of 10. Correlations 
between all measures are presented in online supplementary 
table 2.
Correlations remained strong when adjusting for date of 
assessment (all p’s<0.001). In the subsample of e-cigarette only 
users (ie, those whose recent nicotine exposure was not from 
tobacco), all measures remained significantly correlated with 
cotinine (p’s<0.001): SPM r=0.52, SPD r=0.49, days per 
month r=0.54, HVI r=0.43, ECDI r=0.41, EASI r=0.42.
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Table 1 Cotinine levels by e-cigarette use characteristics
salivary cotinine (ng/ml)
n (%) M (sd) Median Range
Full sample 173 (100.0)
Current nicotine use
  All e-cigarettes contain nicotine 72 (41.6) 61.9 (87.3) 17.4 0–369.3
  Some contain nicotine 67 (38.7) 31.3 (111.7) 0.0 0–864.6
  None contain nicotine 13 (7.5) 2.3 (7.7) 0.0 0–27.9
  Unknown nicotine content 21 (12.1) 2.5 (9.6) 0.0 0–44.1
Type of e-cigarette used
  Customisable/Mod 56 (32.4) 59.5 (133.5) 6.5 0–864.6
  Juul 38 (22.0) 54.3 (90.1) 6.1 0–302.8
  Vape pen 59 (34.1) 18.2 (38.9) 0.0 0–161.5
  Other or unknown 20 (11.6) 8.5 (23.2) 0.0 0–98.8
Daily/non-daily e-cigarette use
  Daily 25 (14.5) 114.6 (103.1) 88.8 0–369.3
  Non-daily 148 (85.5) 25.5 (83.7) 0.55 0–864.6
e-Cigarette only users 144 (83.2)
Current nicotine use
  All e-cigarettes contain nicotine 51 (35.4) 47.4 (82.3) 9.1 0–369.3
  Some contain nicotine 60 (41.7) 24.9 (114.1) 0.0 0–864.6
  None contain nicotine 12 (8.3) 0.1 (0.5) 0.0 0–1.7
  Unknown nicotine content 21 (14.6) 2.5 (9.6) 0.0 0–44.1
Type of e-cigarette used
  Customisable/Mod 48 (33.3) 51.5 (137.3) 3.7 0–864.6
  Juul 31 (21.5) 36.1 (75.1) 1.5 0–283.0
  Vape pen 49 (34.0) 7.6 (26.7) 0.0 0–161.5
  Other or unknown 16 (11.1) 0.3 (0.9) 0.0 0–3.3
Daily/non-daily e-cigarette use
  Daily 15 (10.4) 93.0 (100.4) 57.8 0–369.3
  Non-daily 129 (89.6) 19.9 (85.6) 0.0 0–864.6
Table 2 Distributions of key measures
Full sample (n=173) e-cigarette only users (n=144)
M (sd) Median Range M (sd) Median Range
Cotinine 38.4 (92.0) 2.1 0–864.6 27.5 (89.7) 0.0 0–864.6
Ln Cotinine* 1.8 (2.0) 1.1 0–6.8 1.3 (1.8) 0.0 0–6.8
Days per month* 15.4 (9.8) 15.0 0–30.0 14.2 (9.6) 12.0 0–30.0
SPD 3.2 (5.6) 1.4 0–54.1 2.4 (3.6) 1.1 0–25.0
Ln SPD* 1.1 (0.8) 0.9 0–4.0 0.9 (0.7) 0.8 0–3.3
SPM 74.7 (167.1) 17.3 0–1624.3 52.5 (103.1) 13.4 0–725.0
Ln SPM* 3.0 (1.7) 2.9 0–7.4 2.7 (1.6) 2.7 0–6.6
ECDI* 3.4 (3.9) 2.0 0–16.0 2.7 (3.3) 1.0 0–15.0
EASI* 24.6 (25.0) 17.0 0–100.0 20.7 (22.9) 11.0 0–100.0
HVI* 1.8 (2.3) 1.0 0–10.0 1.5 (2.0) 1.0 0–9.0
*Used in analyses.
EASI, E-cigarette Addiction Severity Index; ECDI, Penn State Electronic Cigarette Dependence Index; HVI, Heaviness of Vaping Index; SPD, Sessions per Day; SPM, Sessions per Month.
dIsCussIon
In a sample of adolescent past month e-cigarette users, brief, 
single-item measures (ie, days per month and the EASI) 
performed comparably with more complex indices for measuring 
e-cigarette use frequency and dependence, as validated by sali-
vary cotinine. The measures evaluated in this study vary in their 
length and complexity. The frequency of use measures each 
required estimation of use over a week or a month’s time, while 
the addiction/dependence measures ranged from a single item 
to 10 items. All measures correlated significantly with cotinine 
as a biomarker of nicotine exposure, suggesting that they can be 
used in research and clinical practice to document adolescents’ 
frequency of use and the development of e-cigarette addiction. 
This is the first study to validate multiple measures of adoles-
cent e-cigarette use and addiction. Use of common, validated 
measures in research will aid comparison across studies.
Among the frequency measures, correlations were approx-
imately equivalent (r’s=0.57-.59). As measured in the present 
study, SPD and SPM reflect the nuances of adolescents’ e-cig-
arette use patterns across different days of the week. However, 
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these measures require 7–8 items. Therefore, the single-item 
measure of days per month may be the most practical and 
performed equally well.
Consistent with our prior research with adolescent combustible 
cigarette smokers (where participants were asked to rate their 
self-perceived level of addiction on tobacco cigarettes on a Likert 
scale from ‘not at all addicted’ to ‘totally addicted’; r=0.56),20 
self-described degree of addiction (the EASI) was significantly 
correlated with cotinine levels in adolescent e-cigarette users. 
This single-item self-report measure is quick to complete, easy 
to incorporate in clinical and research assessments, and may be 
useful in identifying youth at risk of continued use and in need of 
treatment. The single-item EASI measure performed just as well 
in its association with cotinine as the more extensive 10-item 
ECDI and 2-item HVI. The ECDI captures a variety of aspects 
of dependence, including length of e-cigarette use sessions, 
nighttime and morning use, cravings and withdrawal symptoms. 
Developed for use with adults, items were derived from previ-
ously validated measures such as the Fagerström Test of Nicotine 
Dependence21 and the Hooked on Nicotine Checklist.28 As such, 
the ECDI may serve as a relatively comprehensive measure of 
dependence symptoms, and our findings support its utility with 
adolescent e-cigarette users.
The present study fills gaps in the literature by evaluating 
multiple measures of adolescents’ e-cigarette use frequency 
and the development of addiction/dependence with validation 
against cotinine as a biomarker of nicotine exposure. We used 
cotinine to validate self-report measures because it measures 
exposure to nicotine, the addictive component of e-cigarettes.11 
However, there are a few important considerations when 
using cotinine to validate self-reported e-cigarette use. First, 
high cotinine levels may also reflect combustible cigarette use, 
which was reported in the past 24 hours by 4.6% of the sample. 
However, in the subsample of e-cigarette only users, correlations 
between self-report measures and cotinine remained statistically 
significant and relatively high, suggesting that the self-report 
measures of e-cigarette dependence/addiction are not simply 
reflecting dependence on nicotine in combustible tobacco. 
Second, cotinine would not be elevated among users who only 
used nicotine-free e-liquid (n=13, 7.5% in our sample), even if 
they used frequently. However, we included this group in the 
analysis because frequency and dependence should be (and in 
fact were) low in this small subgroup, likely because nicotine is 
the addictive component of e-cigarettes.
With broad applicability, the measures appear to have utility 
among both adolescent dual users and e-cigarette only users. 
The study was adequately powered to test the significance of 
correlations among the measures of interest. Although partic-
ipants were recruited from the San Francisco Bay Area, the 
demographics of our sample generally reflect those of adoles-
cent e-cigarette users in the USA (ie, primarily white, male, 
older adolescents).29 Nonetheless, future research could aim 
to validate measures in more diverse samples. Finally, since 
the completion of our trial, a new measure of e-cigarette 
dependence, the PROMIS-E,30 31 has been introduced and 
future research could include this and additional measures. 
However, our results suggest that brief measures of e-cigarette 
use frequency and dependence (eg, days of use per month, the 
EASI) are valuable screening tools and predictive measures for 
both clinicians and researchers in identifying particularly high-
risk e-cigarette use among adolescents.
ConClusIons
Use of common measures of e-cigarette frequency and dependence 
will aid clinicians and researchers in documenting exposure and 
identifying those adolescents at greatest risk for becoming addicted. 
The present study found days of use per month and self-reported 
degree of e-cigarette addiction performed comparably to the more 
extensive measures of e-cigarette use frequency and dependence 
in estimating cotinine as a biomarker of actual nicotine exposure. 
Therefore, we recommend the EASI and days per month as brief 
general measures.
What this paper adds
 ► Adolescent e-cigarette use is a public health concern.
 ► Electronic-cigarette (e-cigarette) use exposes adolescents to 
nicotine and toxicants.
 ► Validated measures of adolescent e-cigarette use frequency 
and dependence are needed in research and clinical practice 
to identify hazardous use patterns.
 ► We examined correlations between nicotine exposure 
determined by salivary cotinine and measures of adolescent 
e-cigarette use and dependence.
 ► Brief, single-item measures (ie, days per month and the 
E-cigarette Addiction Severity Index) showed utility in 
measuring e-cigarette use frequency and dependence.
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